Lopez, Juanita

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 2,552

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 969

Combine and conquer: challenges for targeted therapy combinations in early phase trials

Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology

Lung Cancer Treatments and MutationsStatistical Methods in Clinical Trials

Cited by 394

Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158

Marabelle, A., Fakih, M. G., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 104

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 78

725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Banerjee, S., Grochot, R., Shinde, R., Lima, J., Krebs, M., Rahman, R., Little, M., Tunariu, N., Curcean, A., Badham, H., et al. (2021) · Annals of Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 17

Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 10